Cipla (EU) Limited, a wholly owned subsidiary of Cipla Limited, in the UK has agreed to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical Co. Ltd., a subsidiary of Cipla EU in China.

Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.

Cipla (Jiangsu) Pharmaceutical Co. Ltd. is a joint venture between Cipla (EU) Limited and Jiangsu XiDi Pharmaceuticals Co. Ltd. (formerly known as Jiangsu Acebright Pharmaceuticals Co. Ltd.), incorporated in 2019 in China for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services, and analytical development services.

The turnover is nil as yet to commence its operations and the cost of the acquisition is US $16.40 million.